Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preemptive Piroxicam-beta-Cyclodextrin for Bleaching-Induced Tooth Sensitivity
NCT03153657Phase 3Completed
- Sponsor
- Universidade Federal de Sergipe
- Start
- Dec 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of piroxicam in dentin hypersensitivity (DH), sponsored by Universidade Federal de Sergipe. Primary endpoint: Risk to Tooth sensitivity at 24 hours. Started Dec 2016; status: completed.
02
Drugs
piroxicam
03
Conditions
dentin hypersensitivity (DH)
Beyond the preview
Go deeper on NCT03153657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03153657.